TY - JOUR
T1 - A systematic review of tegaserod for the treatment of irritable bowel syndrome
AU - Jones, BW
AU - Moore, David
AU - Robinson, Suzanne
AU - Song, Fujian
PY - 2002/10/1
Y1 - 2002/10/1
N2 - AIM: To assess the clinical effectiveness of tegaserod for the treatment of irritable bowel syndrome (IBS). DESIGN: Systematic review. SETTING: Six placebo-controlled, randomized controlled trials (RCTs) retrieved from electronic searches (Medline, Embase, FDA website) and hand-searching. MAIN OUTCOME MEASURES: Any outcome was accepted. RESULTS: In a small pharmacodynamic study, tegaserod 4 mg/day accelerated orocecal transit compared with placebo, but did not affect gastric emptying rate and colonic transit. Five placebo-controlled studies evaluated Subject's Global Assessment of gastrointestinal (GI) symptoms in predominantly female patients who fulfilled Rome criteria for constipation-predominant IBS. Responder rates were higher with tegaserod 1-24 mg/day than with placebo, although it was not possible in this review to evaluate the consistency of this effect, to fully quantify the effect size, or identify patients who may gain most benefit from this treatment. CONCLUSION: Currently published data on tegaserod for IBS are limited (two of six RCTs published in full, four as abstracts). Tegaserod may be an appropriate treatment for occasional use for relief of GI symptoms associated with constipation-predominant IBS. Further research, comparing tegaserod with alternative treatments for GI symptoms of IBS, should help define the place of this drug in therapy.
AB - AIM: To assess the clinical effectiveness of tegaserod for the treatment of irritable bowel syndrome (IBS). DESIGN: Systematic review. SETTING: Six placebo-controlled, randomized controlled trials (RCTs) retrieved from electronic searches (Medline, Embase, FDA website) and hand-searching. MAIN OUTCOME MEASURES: Any outcome was accepted. RESULTS: In a small pharmacodynamic study, tegaserod 4 mg/day accelerated orocecal transit compared with placebo, but did not affect gastric emptying rate and colonic transit. Five placebo-controlled studies evaluated Subject's Global Assessment of gastrointestinal (GI) symptoms in predominantly female patients who fulfilled Rome criteria for constipation-predominant IBS. Responder rates were higher with tegaserod 1-24 mg/day than with placebo, although it was not possible in this review to evaluate the consistency of this effect, to fully quantify the effect size, or identify patients who may gain most benefit from this treatment. CONCLUSION: Currently published data on tegaserod for IBS are limited (two of six RCTs published in full, four as abstracts). Tegaserod may be an appropriate treatment for occasional use for relief of GI symptoms associated with constipation-predominant IBS. Further research, comparing tegaserod with alternative treatments for GI symptoms of IBS, should help define the place of this drug in therapy.
UR - http://www.scopus.com/inward/record.url?scp=0036405052&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2710.2002.00426.x
DO - 10.1046/j.1365-2710.2002.00426.x
M3 - Article
C2 - 12383135
SN - 1365-2710
SN - 1365-2710
SN - 1365-2710
SN - 1365-2710
SN - 1365-2710
SN - 1365-2710
SN - 1365-2710
SN - 1365-2710
SN - 1365-2710
SN - 1365-2710
SN - 1365-2710
SN - 1365-2710
SN - 1365-2710
SN - 1365-2710
SN - 1365-2710
SN - 1365-2710
SN - 1365-2710
SN - 1365-2710
SN - 1365-2710
SN - 1365-2710
SN - 1365-2710
SN - 1365-2710
SN - 1365-2710
SN - 1365-2710
SN - 1365-2710
SN - 1365-2710
SN - 1365-2710
SN - 1365-2710
VL - 27
SP - 343
EP - 352
JO - Journal of Clinical Pharmacy and Therapeutics
JF - Journal of Clinical Pharmacy and Therapeutics
IS - 5
ER -